Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

European Firms Combat Antibiotic Resistance

by Michael McCoy
May 28, 2012 | A version of this story appeared in Volume 90, Issue 22

Europe’s Innovative Medicines Initiative is launching a $281 million program in which academics and five drug companies will tackle the growing problem of antibiotic resistance. IMI, a public-private partnership, will provide $137 million of the funding, and the five companies—Glaxo­SmithKline, AstraZeneca, Janssen, Sanofi, and Basilea Pharmaceutica—will provide the rest. Among the program’s goals are better-designed clinical trials for testing experimental antibiotics against resistant bacteria such as Staphylococcus aureus. IMI says Europe saw 25,000 deaths in 2007 due to antimicrobial resistance.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.